AUTUMN MEJIA: Open Payments
NPI 1417615303 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,651 in 98 payments from 26 companies in 2025. Trend: 2023 $0 · 2024 $550 · 2025 $1,651
Food & beverage: $1,651
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $228 |
| Novo Nordisk Inc | 14 | $217 |
| PFIZER INC. | 15 | $201 |
| ABBVIE INC. | 15 | $201 |
| Lilly USA, LLC | 11 | $172 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $97 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $75 |
| Dexcom, Inc. | 3 | $62 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| KYOWA KIRIN, INC. | 2 | $42 |
Products named: FARXIGA, MOUNJARO, JARDIANCE, NURTEC ODT, XIFAXAN, QULIPTA, Ozempic, UBRELVY.
Industry payments across VA — which companies pay providers there.
